Who owns ROCKET PHARMACEUTICALS, INC. (ITEK)? Elite investor 13F holders

5 tracked elite investors reported holding ROCKET PHARMACEUTICALS, INC as of 2026-06-30, including Maverick Capital, D.E. Shaw, Renaissance Technologies LLC, Tudor Investment, Ancora Advisors / Ancora Holdings. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.

5 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States. It develops in vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading…

Reported holders and securities, including exits (up to 20)

Reported holders and securities, including exits (up to 20)
InvestorSecurityInstrumentReport periodFiledValueQuantityUnitsChangeSource
Maverick CapitalROCKET PHARMACEUTICALS INCSHARE2026-06-302026-08-14 00:00:0013419953.00 USD3923963.000000SharesaddOriginal filing
D.E. ShawROCKET PHARMACEUTICALS INCSHARE2026-06-302026-08-14 00:00:003250888.00 USD950552.000000SharesreduceOriginal filing
Renaissance Technologies LLCROCKET PHARMACEUTICALS INCSHARE2026-06-302026-08-13 00:00:002711971.00 USD792974.000000SharesaddOriginal filing
Tudor InvestmentROCKET PHARMACEUTICALS INCSHARE2026-06-302026-08-14 00:00:00172686.00 USD50493.000000SharesholdOriginal filing
Ancora Advisors / Ancora HoldingsWTS ROCKET PHARMACEUTICALS INCSHARE2026-06-302026-08-14 00:00:0022.00 USD6000.000000SharesholdOriginal filing

Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.

This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.

How to read the data · Disclaimer

Read as Markdown